# Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)

> **NCT07183878** · NA · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 138 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- High-Risk Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- High-Risk Myelodysplastic Syndromes

## Interventions

- **DRUG:** Venetoclax
- **OTHER:** None-placebo

## Key facts

- **NCT ID:** NCT07183878
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-20
- **Primary completion:** 2027-08-20
- **Final completion:** 2028-08-20
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07183878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07183878, "Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT07183878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*